Clinical trials: Neck Cancer
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Head and Neck Cancer
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate the efficacy and safety of adjuvant Toripalimab in high-risk recurrent/secondary HNSCC after salvage surgery.
- Trial name
- RePASS (NCT04126460)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Cancer of Cervix
Follow-up of Cell Changes in the Cervix
The purpose of the study is to follow up on cell changes detected in the cervical cancer screening program, to investigate whether they are handled with adequate quality.
- Trial name
- NCT05709730
- Testing
- HPV genotyping
- Where
- Sweden
- Volunteers
- 885 people
- Sponsor
- Karolinska University Hospital
Esophageal Cancer, Recurrence
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor.
- Conditions
- Esophageal Cancer, Recurrence, DNA Methylation
- Trial name
- NCT06476067
- Testing
- Surgery
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Physician, Surgeon
Deformable Tissue Modelling and Augmented Reality Based Guidance for Head and Neck Tumor Re-Resection Task
Head and neck cancers have one of the highest recurrence rates among solid malignancies, and recurrence is strongly correlated with overall survival.
- Conditions
- Physician, Surgeon, Resident Doctor, Resident Surgeon
- Trial name
- SPeAR (NCT07686211)
- Testing
- Augmented Reality
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University Medical Center
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Lung Cancer, Small Cell, Pancreatic Cancer
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Accurate evaluation of activity status is an important part of the assessment of people with cancer. Clinician assessments currently used are valuable but have limitations; in particular, assessment only occurs when the patient…
- Conditions
- Lung Cancer, Small Cell, Pancreatic Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- WATTOX (NCT04440800)
- Testing
- Wearable activity tracker - FitBit
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cervical Intraepithelial Neoplasia, Cervical Neoplasms
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix
- Trial name
- NCT04266093
- Testing
- GeneTherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00041093
- Testing
- Docetaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
Lung Cancer, Esophageal Cancer
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT.
- Conditions
- Lung Cancer, Esophageal Cancer, Thoracic Cancer, Hodgkin Lymphoma
- Trial name
- NCT04072393
- Testing
- Home-based cardiac rehabilitation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort…
- Trial name
- NCT05674526
- Testing
- WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allotera Therapeutics
Thyroid Nodule
In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules
Thyroid nodules are common in clinical practice. Head and neck ultrasound is recommended as a routine examination for all patients with thyroid lesions.
- Trial name
- THYNODE (NCT04730726)
- Testing
- MSOT Acuity Echo
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Head and Neck Cancers
SOMESThesia and ALIMentation
Cancer patients are at high risk for undernutrition. A study with head and neck cancer patients showed that 50% suffered from undernutrition (Prevost et al., 2014).
- Trial name
- SOMEST'ALIM (NCT05272917)
- Testing
- Sensorial tests, food preferences questionnaires
- Where
- 2 sites in France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Colon Cancer Metastatic, Head and Neck Cancer Metastatic
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors.
- Conditions
- Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NEO (NCT03265080)
- Testing
- ADXS-NEO, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Advaxis, Inc.
HNSCC
Dose-Effect Relation of Salivary Gland Irradiation
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood.
- Trial name
- NCT03367780
- Testing
- PSMA PET/CT-scan
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Nasopharyngeal Carcinoma
Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma
Radiotherapy is an important treatment for initial distant metastases nasopharyngeal carcinoma. Total dose and fraction size are important prognostic factors for survival, although to our knowledge the optimal model has not been…
- Trial name
- NCT03598218
- Testing
- Hypofraction radiation, Standard dose IMRT
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Thyroid Cancer, Salivary Gland Cancer
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
- Trial name
- iPRIME (NCT03360890)
- Testing
- Pembrolizumab, Docetaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.